hey guys here's a snippit of wilson's latest coverage on CXS:
Recommendation
Our view is that ODAC will recommend Omapro. Although valid issues were raised on efficacy and trial conduct, ODAC did not contest Omapros benefit: risk ratio and the panel will be mindful that there is no alternative, approved therapy for the patients they are discussing. There is an opportunity to invest at less than half the fundamental asset value for investors prepared to take on high risk at appropriate weightings. The FDA delay has introduced risk to launch timing and that of a potential capital raising by ChemGenex. These are minor impacts but we give both appropriate treatment: launch pushed into 1HFY11; and a $15M capital raise, perhaps as early as May.
Our BUY rating is
maintained on ChemGenex. Target is revised to $1.70 per share.
- Forums
- ASX - By Stock
- CXS
- latest wilsonhtm report
latest wilsonhtm report
-
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CXS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online